well guys.....one thing that always hurt us was/ is the fact we don't have access to the agreements. we can speculate all we want and that's all it is. I personally think we could use the conservative estimates of Angelo if nothing else, the fact we are getting a double bite at the apple. everyone is calculating off royalties and I keep saying the huge unknown is the % of cost plus. thats automatic profit built in and should come from day 1 on the manufacturing side.
It is because of this, one needs to look closely at what was said. They already indicated they felt they had enough cash to get through to June. FROM WHERE? they only reported 2.2 million cash on hand. so clearly they are anticipating enough revenue for Focalin with exclusivity to bridge this gap. They didn't say anything further because then Seroquel becomes a factor from day 1 as I indicated.
the indicator was they states they would use the ATM to bridge any gap. again, what does this tell us? in my opinion that states they dont anticipate needing significant cash. other wise they would have said another secondary offering may be possible under the shelf just like they did back in July. the fact they indicated they would use the ATM indicates they are not anticipating needing significant dilution other wise they would do another offering like they did.
I think we are in for a rough couple weeks but I do hope the company gives clearer guidance in the 1QE17 which if all these numbers come in we should trade much higher just on the known revenue increases. we should be cash neutral and possibly profitable by year end. at which point any additional ANDA approval or Rexista deal would be gravy.
now, if our cash and sales are going to be that good this year will the PPS reflect that? who knows.
News 
Market Data 
Discover 
AI
